What is the history of 2q23.1 Microdeletion Syndrome?

2q23.1 Microdeletion Syndrome was first clinically characterized in the early 2000s, primarily identified through the advancement of high-resolution chromosomal microarray analysis. This rare genetic condition, caused by a small deletion on the long arm of chromosome 2, is now recognized as a distinct clinical entity characterized by intellectual disability, growth delays, and specific behavioral features.

When was 2q23.1 Microdeletion Syndrome first identified?

The medical literature began to formally document 2q23.1 Microdeletion Syndrome around 2007. Researchers, including Walter et al., utilized comparative genomic hybridization (CGH) to identify patients with overlapping deletions in the 2q23.1 region. Before this era of molecular cytogenetics, many individuals with 2q23.1 Microdeletion Syndrome remained undiagnosed or were categorized under generic developmental delay labels because traditional karyotyping could not detect such small, submicroscopic deletions.

How has our understanding of 2q23.1 Microdeletion Syndrome evolved?

As genetic sequencing technology transitioned from basic karyotyping to chromosomal microarray (CMA) and eventually whole-exome sequencing, our grasp of 2q23.1 Microdeletion Syndrome expanded significantly. We now know that the MBD5 gene, located within the deleted region, plays a critical role in the neurological presentation of the condition. Historically, the syndrome was often misdiagnosed as Autism Spectrum Disorder or Rett syndrome due to overlapping phenotypic traits like hand-wringing and speech delays.

What are the historical milestones in characterizing this condition?

• 2007: Initial clinical reports define the critical region on chromosome 2q23.1.


• 2008-2010: Identification of the MBD5 gene as the primary driver of the clinical symptoms associated with 2q23.1 Microdeletion Syndrome.


• 2015-Present: Increased use of next-generation sequencing has allowed for the identification of smaller, atypical deletions, broadening the clinical spectrum.

How has patient advocacy shaped the history of 2q23.1 Microdeletion Syndrome?

The history of 2q23.1 Microdeletion Syndrome is inseparable from the rise of digital patient registries. Platforms like DiseaseMaps.org have been instrumental, connecting families who previously felt isolated by the rarity of the condition. With 4 community members currently sharing their experiences on DiseaseMaps.org, the collective patient voice has helped clinicians better understand the natural history and variability of the syndrome beyond initial laboratory reports.

Next steps

• Consult a clinical geneticist to confirm a diagnosis through chromosomal microarray analysis.


• Connect with the 2q23.1 Microdeletion Syndrome community on platforms like DiseaseMaps.org to share resources.


• Maintain a consistent record of developmental milestones to assist your care team in creating a personalized therapy plan.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: The portal for rare diseases and orphan drugs


• OMIM (Online Mendelian Inheritance in Man): Entry #612703


• PubMed: Clinical studies on MBD5-related neurodevelopmental disorders